CellPoint, a cell therapy company developing CAR-T therapeutics for use at the point-of-care, has signed an agreement with Lonza’s Personalized Medicine Business Unit to employ Lonza’s Cocoon Platform for clinical manufacturing of CellPoint’s CAR-T cell therapies at the point-of-care, more rapidly and at lower cost.   One of the key hurdles in making CAR-T immunotherapies more accessible to larger patient populations is the difficulty in manufacturing at-scale, robustly, and ...